Publication Cover
Natural Product Research
Formerly Natural Product Letters
Volume 36, 2022 - Issue 4
205
Views
3
CrossRef citations to date
0
Altmetric
Short Communications

Docking studies of sesquiterpene lactones isolated from Ambrosia maritima L. reveals their potential anti-inflammatory and cytotoxic activities

, , , ORCID Icon &
Pages 1078-1083 | Received 11 Jun 2020, Accepted 05 Nov 2020, Published online: 19 Nov 2020
 

Abstract

Five sesquiterpene lactones were isolated and identified from Ambrosia maritima L. Hymenin showed highest cytotoxic activity against HCT-116, A-549, and MCF-7 cell lines (IC50= 3.83 ± 0.2, 5.48 ± 0.3, 10.1 ± 0.6 µg/mL, respectively). Damsin has significant COX-2 inhibitory activity (IC50=33.97 ± 1.62 µg/mL) while hymenin showed highest selectivity to COX-1 (IC50 = 18.21 µg/mL) and significant inhibition of NO (IC50=18.19 ± 0.75 µg/mL). The docking study revealed nice fitting into COX-1/2 and a higher binding affinity for maritimolide towards human Src kinase compared to the native ligand, Bosutinib. Results suggested that both COXs/Src kinase inhibition could contribute even partially to the overall mechanism of cytotoxic activity of the five compounds. The structure-activity relationship revealed that α-methylene-γ-lactone moiety enhances the cytotoxic activity, OH group at C-1 increase activity of hymenin. However, the reduction of the double bond at C-2 as in damsin resulted in a significant decrease in activity against HCT-116 and MCF-7 cells.

Graphical Abstract

Acknowledgements

Our great thanks for Dr. Abdel Haleem Mohammed for help in plant identification.

Disclosure statement

No potential conflict of interest was reported by the authors.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.